Corline Biomedical AB
CLBIO
Rank in Stocks
#24315
Corline Biomedical AB is a company dedicated to the creation, production, and... Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
Share Price
$1.31
Last synced: 2026-11-09
Market Cap
$34.13M
Change (1 day)
-0.25%
Change (1 year)
-35.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Corline Biomedical AB (CLBIO)
Category
Healthcare
EPS for Corline Biomedical AB (CLBIO)
EPS as of June 2026 TTM: $-0.05
According to Corline Biomedical AB's latest financial reports, its current EPS (TTM) is $-0.05. At the end of 2025 the company had an EPS of $-0.06, an increase over its 2024 EPS of $-0.10.
EPS history for Corline Biomedical AB from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.05 | -17.50% |
| 2025 | $-0.06 | -33.51% |
| 2024 | $-0.10 | 1,057.83% |
| 2023 | $-0.01 | -179.05% |
| 2022 | $0.01 | -127.93% |
| 2021 | $-0.04 | -25.98% |
| 2020 | $-0.05 | -16.86% |
| 2019 | $-0.06 | 23.94% |
| 2018 | $-0.05 | -31.72% |
| 2017 | $-0.07 | 52.64% |
| 2016 | $-0.05 | -41.32% |
| 2015 | $-0.08 | 65.50% |
| 2014 | $-0.05 | -15.30% |
| 2013 | $-0.06 | 175.12% |
| 2012 | $-0.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -31,736.36% |
US
|
|
| $-7.07 | 14,182.83% |
US
|
|
| $-5.29 | 10,586.87% |
AU
|
|
| $12.88 | -26,120.40% |
BE
|
|
| $21.56 | -43,655.56% |
NL
|
Questions about Corline Biomedical AB's earnings per share (EPS)
What is Corline Biomedical AB's earnings per share (EPS)?
Corline Biomedical AB's earnings per share (EPS) over the last twelve months is $-0.05, as of Jun 2026.
What was Corline Biomedical AB's earnings per share (EPS) in 2025?
In 2025, Corline Biomedical AB's earnings per share (EPS) was $-0.06, compared with $-0.10 in 2024.
How has Corline Biomedical AB's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Corline Biomedical AB's earnings per share (EPS) was highest in 2022 ($0.01) and lowest in 2024 ($-0.10).
How does Corline Biomedical AB's earnings per share (EPS) compare with similar companies?
Corline Biomedical AB's earnings per share (EPS) ($-0.05) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.